Oramed files Form 144 to sell 137,000 shares

Oramed Pharmaceuticals submitted a Form 144 disclosing proposed sales of common stock.

Accepted by SEC EDGAR 07/01/2026 - 12:03 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Oramed Pharmaceuticals submitted a Form 144 disclosing proposed sales of common stock. The filing lists 137,000 shares alongside a $658,970.00 value and a larger share figure 40,926,081 dated 07/01/2026. It also records 108,000 shares issued upon RSU vesting on 05/01/2023 and 50,000 shares acquired on 07/01/2026 upon option exercise.

Key Figures

Registered/offered shares (table line): 137,000 shares Associated value: $658,970.00 Larger share figure: 40,926,081 +2 more

5 metrics

Registered/offered shares (table line) 137,000 shares listed with Oppenheimer & Co. entry

Associated value $658,970.00 same table row dated 07/01/2026

Larger share figure 40,926,081 table entry dated 07/01/2026

RSU shares issued 108,000 shares issued upon vesting of RSUs on 05/01/2023

Option exercise shares acquired 50,000 shares acquired upon exercise of employee stock options on 07/01/2026

Key Terms

RSUs, employee stock options, Form 144

3 terms

RSUs financial

"Shares issued upon vesting of RSUs"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

employee stock options financial

"Shares acquired upon exercise of employee stock options"

Employee stock options are contracts that give workers the right to buy a company's shares at a set price sometime in the future, like a coupon that lets you purchase stock at today’s price later on. Investors care because they align employees’ incentives with company performance and create a potential future claim on shares that can reduce existing owners’ percentage and add to a company’s reported compensation costs.

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Oramed's Form 144 (ORMP) disclose about shares to be sold?

The filing shows 137,000 shares associated with a $658,970.00 value and a larger share figure of 40,926,081 with date 07/01/2026. It lists methods of sale but does not specify buyer identity or exact timing.

How many shares were issued on vesting of RSUs according to the filing?

The document records 108,000 shares issued upon vesting of RSUs on 05/01/2023. That entry is described as "No consideration, shares issued upon vesting of RSUs" in the excerpt.

What option exercise activity does the Form 144 show for ORMP?

The filing records acquisition of 50,000 shares upon exercise of employee stock options on 07/01/2026, described as a cash payment upon exercise of stock options.

Does the excerpt state how sales will be executed or who receives proceeds?

The excerpt lists securities to be sold and methods like RSU vesting and option exercise but does not specify the purchasers or assign proceeds recipients; cash‑flow treatment is not shown in the provided excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001573235
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ORAMED PHARMACEUTICALS INC.
SEC File Number	001-35813
Address of Issuer	1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NEW YORK 10036
Phone	646-844-1164
Name of Person for Whose Account the Securities are To Be Sold	Hexter Joshua
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Oppenheimer & Co. Inc. 85 Broad St, New York NY 10004	137000	658970.00	40926081	07/01/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/01/2023	Shares issued upon vesting of RSUs	ORAMED PHARMACEUTICALS INC.			108000	05/01/2023	No consideration, shares issued upon vesting of RSUs
Common Stock	07/01/2026	Shares acquired upon exercise of employee stock options	ORAMED PHARMACEUTICALS INC.			50000	07/01/2026	Cash payment upon exercise of stock options

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities are being sold pursuant to a Rule 10b51 trading plan adopted on 03-30-2026.
Date of Notice	07/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/30/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Joshua Hexter By: /s/ Yohanan Azriel Title: Authorized Signatory, Oppenheimer Israel (pursuant to delegation)
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)